scb-2023
Vaccineexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Aug 17, 2023 (NCT05926440)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
immunity, active - sars-cov-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06567457 | Phase 3 | Oct 31, 2023 | Clover Biopharmaceuticals |
| NCT05926440 | Phase 3 | Aug 17, 2023 | Clover Biopharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clover Biopharmaceuticals | For profit | 2 | 2 | 1 | 2023 |
1 organizations
Page 1 / 1